Cencora: The Specialty Shift Is Working. The Question Is Whether the Stock Has Noticed.

Cencora announced a new cell and gene therapy enablement service this year, positioning itself as the infrastructure partner that helps hospitals build programs for treatments that require ultra-cold storage, individualized patient tracking, and complex reimbursement navigation. The announcement is part of a broader strategy — one that has been underway for two years and is now showing up in the quarterly numbers.

The problem for investors is that Cencora trades like a business that hasn't changed.

Cencora is the largest specialty pharmaceutical distributor in the United States. It moved approximately $321 billion of product through the system last year — branded and generic drugs, injectables, over-the-counter health products, and the fast-growing specialty segment that includes cancer treatments, biologics, and weight-loss medications. For a company that size, the margins look almost inconceivable. Gross profit comes in around 3.8% of revenue. Operating margin sits near 0.85%. A $100 sale produces 85 cents of operating income. That's not an error in the math — that's the model. Distributors make money on volume, and they need enormous volume.

But the model is changing. Cencora, formerly AmerisourceBergen before a 2023 rebranding, has spent the past two years buying its way into higher-margin specialty businesses. In February 2026, it completed the OneOncology acquisition, adding a leading oncology practice management platform. These aren't distribution plays. They're higher-margin healthcare services businesses that produce revenue the old gross-margin denominator can't properly measure.

The effect is visible in the financials. In the third quarter of fiscal 2026, which ended June 30, Cencora reported revenue of $84.8 billion, up 5% year over year. Adjusted gross profit grew 23% to $3.5 billion, expanding the gross profit margin by 61 basis points to 4.16%. That's not a dramatic jump in absolute terms, but for a business that moves nearly a trillion dollars annually, every basis point of margin expansion translates into hundreds of millions in profit. Adjusted operating income rose 17% to $1.2 billion. Adjusted diluted EPS came in at $4.48, up from $4.00 a year earlier.

Management raised full-year adjusted EPS guidance to a range of $17.65 to $17.90. Free cash flow for the trailing twelve months came in at $4.06 billion — a 256% improvement year over year, which reflects the reversal of heavy working capital demands from earlier in the acquisition cycle.

That's the operating side. The stock hasn't rewarded it.

Cencora shares trade around $331. That's down about 6% over the past 120 days and roughly flat year-to-date. The stock hit a 52-week high of $377 last winter and hasn't recovered. At a $63 billion market capitalization, Cencora trades at roughly 24 times trailing earnings and 25 times forward earnings. For context, rival distributor McKesson trades at about 23 times trailing earnings but a significantly cheaper 15 times EV/EBITDA, while Cencora runs at nearly 22 times EV/EBITDA. Cencora is paying a premium for what the market perceives as a slower-growth distributor, even as the company quietly reshapes itself.

Here's the disconnect. The specialty acquisition strategy is not a narrative Cencora is selling in investor presentations. It's showing up in the margin trajectory. The gross margin has expanded for multiple consecutive quarters — from 3.48% adjusted in Q1 fiscal 2026 to 4.31% in Q2 to 4.16% in Q3. The OneOncology integration is temporarily bumping up operating expenses, which is why Q3 operating expenses jumped 27%, but that's the cost of building the platform, not a sign of operational deterioration. Cencora expects those integration expenses to normalize.

The cell and gene therapy angle that the recent announcement highlights is a longer-term bet, not a near-term revenue driver. Cell and gene therapies are among the most logistically complex treatments in modern medicine. They require cryogenic storage at temperatures below negative 150 degrees Celsius, chain-of-identity tracking that ensures the right treatment reaches the exact patient whose cells were used to manufacture it, and coordination between manufacturers, hospitals, and regulators at a level that traditional drug distribution never required. The market is expected to grow from roughly $9 billion in 2025 toward $47 billion or more by 2035, but most of that growth is still three to five years out.

Cencora's Accelerate Pharmacy Solutions offering — including the CGT enablement service — is infrastructure positioning. It signals that the company intends to own the logistics, financial planning, and readiness assessment layer that health systems will need as CGT adoption accelerates. This isn't revenue you can model today. It's a moat you build before the water rises.

So the actual investment question isn't whether Cencora is interesting. It's whether the specialty shift has moved the needle enough to justify the stock's current valuation, or whether it has moved it enough to argue the stock is mispriced.

On the bull side: Cencora has $63 billion in revenue scale, a 16.3% return on invested capital that dwarfs what you'd expect from a thin-margin distributor, and a margin trajectory that is genuinely expanding, not flat. The company raised EPS guidance for the second consecutive quarter. It has resumed share repurchases with a $1 billion target for calendar 2026 and continues to pay a dividend that's grown for 13 consecutive years. A PEG ratio under 0.65 suggests the multiple is not pricing in aggressive growth already. The specialty MSO acquisitions add recurring revenue streams that are less cyclical than commodity drug distribution.

On the bear side: the margins remain thin. Four percent gross margin is an improvement, but it's still four percent. The OneOncology acquisition added significant debt, which roughly doubled net interest expense. The balance sheet shows $8.9 billion in net debt against only $3.2 billion in equity. That's leverage, and leverage matters when margin expansion stalls. Additionally, Cencora's GLP-1 sales — the diabetes and weight-loss drugs that are driving volume growth — are actually dragging down margins because they're lower-margin products. Growth and profitability are pulling in opposite directions on that specific product line.

There's also the concentration risk. Walgreens Boots Alliance alone accounted for approximately 24% of revenue in 2025, under a contract running through 2029. A relationship that big is both a moat and a dependency.

What would change the call? On the upside, another two to three quarters of margin expansion above 4.25% adjusted gross, combined with integration expenses normalizing, would push operating income growth well above the range management now guides to. That would likely force the multiple to reprice. On the downside, if gross margin stalls or compresses back toward 3.5%, the specialty thesis loses credibility, and the current multiple becomes hard to defend against cheaper peers.

Cencora is not the kind of stock that will generate excitement on a single earnings beat. It's a $320 billion revenue machine that's quietly changing its margin profile by buying higher-margin healthcare services businesses. The market hasn't fully credited the shift yet. Whether that makes it a buying opportunity or simply a slow mover depends on whether you believe the margin trajectory is durable enough to sustain the multiple it already trades at — and whether a specialty distributor running a PEG ratio below 0.7 has room to expand from here if the numbers keep improving.

The next two quarters will tell. Q4 fiscal 2026 results, expected in November, will show whether the full-year EPS guidance is achievable and whether integration expenses from OneOncology are declining. After that, the first full quarter of fiscal 2027 will show whether the margin trajectory continues independently of acquisition-related one-time effects. If the margin expansion holds, the current price reflects a market that hasn't noticed the business it's actually buying.